Ahh, every time I hear about the CUP study failing, it sets me off on my “Abbott & Costello - The Niagara Falls” rant
- The CUP study was not set up or powered to detect significant statistical differences due to the low # of patients (89) being tested and to the many subpopulations where the cancer could originate yet we saw clinical activity i.e. ~ a 30% survival improvement trending toward statistical significance. I would think future investigation is definitely warranted but have not heard anything in those regards. Was wondering why nothing has been started up to now? I realized, hours after the recent Topotarget CC, that it would have been a good time to ask about any further conclusions in regards to belinostat and CUP. Maybe an analyst will ask at the next CC.